STOCK TITAN
  1. Home
  2. News
  3. SNOA

Sonoma Pharmaceuticals Inc. - SNOA STOCK NEWS

Welcome to our dedicated news page for Sonoma Pharmaceuticals (Ticker: SNOA), a resource for investors and traders seeking the latest updates and insights on Sonoma Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sonoma Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sonoma Pharmaceuticals's position in the market.

News
Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
Rhea-AI Summary
Sonoma Pharmaceuticals Expands Microcyn NPWT Solution Product Line in the United States, Showcasing at CPHI Japan and SAWC Spring Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.92%
Tags
none
-
News
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) announced a recent publication in Neurourology and Urodynamics highlighting the potential of Microdox in managing urinary tract infections in children with neurogenic or non-neurogenic bladder dysfunction. Microdox, based on Sonoma's patented Microcyn technology, is licensed for UTI prevention and treatment in Australia and New Zealand. The publication suggests that electrochemically activated solutions like Microdox could significantly improve outcomes for high-risk patients, with evidence from clinical trials supporting its short-term effectiveness. Sonoma aims to enhance patient quality of life through ongoing research and future trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
none
-
News
Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. (SNOA) will be presenting at two upcoming investor conferences in Denver and New York. The company will be presenting at the Trickle Research Spring 2024 Microcap Conference in Denver on April 2nd, 2024, and at the 14th Annual LD Micro Invitational in New York on April 8th - 9th, 2024. Amy Trombly, the CEO of Sonoma, will be leading the presentations at both events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.8%
Tags
conferences
News
Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals
Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) emphasizes the safety advantages of its Microcyn technology products over benzoyl peroxide-containing dermatology products. Recent concerns about benzene formation in popular dermatology products have led to a citizen petition for an FDA recall. Sonoma's Microcyn products, based on hypochlorous acid, are clinically proven to remove microorganisms safely and manage skin irritations without using benzoyl peroxide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
none
-
News
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results
Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA) reported a 7% increase in revenues compared to the previous year and a 15% increase from the prior quarter. The company also saw a 19% improvement in gross margin and a net loss of $1.0 million for the quarter. Sonoma's expansion efforts and cost control measures have positively impacted its financial results. The company also announced the launch of new products and partnerships, including Lumacyn Clarifying Mist and an agreement with NovaBay Pharmaceuticals, Inc. for the sale and marketing of Avenova-branded products in the European Union.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use
Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) has announced the launch of LumacynTM Clarifying Mist, an anti-inflammatory and antibacterial spray for over-the-counter use in the United States. The product is based on Sonoma's patented stabilized hypochlorous acid and is designed to soothe the skin, reduce redness, manage blemishes, and is safe for all ages and skin types. The company aims to provide consumers with a premium skincare product that harnesses the healing properties of their Microcyn technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
none
News
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
Rhea-AI Summary
NovaBay Pharmaceuticals, Inc. (NBY) and Sonoma Pharmaceuticals, Inc. (SNOA) have announced an agreement for the sale and marketing of Avenova-branded products in the European Union. Sonoma will combine its existing eye product Ocudox with Avenova branding and market it through its established European distribution network. Sonoma will pay NovaBay a royalty fee based on net product sales of Ocudox by Avenova, and Sonoma will continue to market its Ocudox product in the European Union.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
none
-
News
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
Rhea-AI Summary
NovaBay Pharmaceuticals, Inc. (NBY) and Sonoma Pharmaceuticals, Inc. (SNOA) have announced an agreement for the sale and marketing of Avenova-branded products by Sonoma in the European Union. The products will combine Sonoma's existing eye product Ocudox with Avenova branding and will be marketed through Sonoma's established European distribution network. Sonoma will manufacture Ocudox by Avenova with packaging similar to NovaBay's Avenova products and will pay NovaBay a royalty fee based on net product sales. This agreement allows NovaBay to capitalize on sales of hypochlorous acid eye care products in the European Union, potentially doubling its sales of Avenova. NovaBay will continue to be the exclusive seller of Avenova branded products in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
none
-
News
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results
Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) announced a 36% gross profit percentage for the quarter, up 1% from the first fiscal quarter 2024. Total operating expenses decreased for the quarter and six months ended September 30, 2023, compared to the same period the prior year. European revenues increased 3% for the quarter and 13% for the six months ended September 30, 2023. The company reported a net loss of $2.9 million for the six months ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News
Sonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall Conference
Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. has announced the U.S. launch of its intraoperative pulse lavage irrigation treatment. The product, developed using Sonoma's Microcyn® Technology, replaces non-antimicrobial saline and aggressive rinsing solutions with a safe and effective solution that can prevent infection and improve healing time. The treatment is cost competitive with IV bags and can be used in a variety of surgical procedures. Sonoma is introducing the product at the Symposium on Advanced Wound Care Fall Conference in Las Vegas and expects it to be ready for commercial use in November 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
none
Stock SNOA logo
Sonoma Pharmaceuticals Inc.

Nasdaq:SNOA

SNOA Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

SNOA Stock Data

2.74M
15.35M
1.56%
1.95%
0.19%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
Woodstock

About SNOA

sonoma pharmaceuticals, inc., develops and produces stabilized hypochlorous acid (hocl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the united states and internationally. the company offers epicyn, an antimicrobial facial cleanser; levicyn, a hypochlorous acid (hocl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; sebuderm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and ceramax, a lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as loyon for the management of skin scal